Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Recruiting now

Conditions studied: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma

In brief

The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

Key facts

Study ID

NCT06357754

Run by

Bristol-Myers Squibb

People needed

50

Starts

2023-10-06

Expected to finish

2038-10-06

Last updated by the study team

2026-01-22

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
• Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.

You may not qualify if…

• Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.
• Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.

Where it is running

• Kantonsspital Aarau — Aarau, Switzerland (enrolling)
• Ut Southwestern — Dallas, Texas, United States (enrolling)
• Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah, United States (enrolling)
• Universitaetsklinikum Essen (AoR) — Essen, Germany (enrolling)
• Toyokawa City Hospital — Toyokawa, Aichi-ken, Japan (enrolling)
• Local Institution - 0016 — Portland, Oregon, United States
• Local Institution - 0004 — Madison, Wisconsin, United States
• Local Institution - 0003 — Kumamoto, Kumamoto, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.